Blog

Aaron Sverdlov: Navigating Cardiotoxicity Risk in Cancer Therapy – The Importance of the HFA-ICOS Score

Aaron Sverdlov/hmri.org.au

Feb 7, 2025, 16:03

Aaron Sverdlov: Navigating Cardiotoxicity Risk in Cancer Therapy – The Importance of the HFA-ICOS Score

Aaron Sverdlov, Professor and Director of Heart Failure and Co-Director at Newcastle Centre of Excellence in Cardio-Oncology, shared an article he and his colleagues authored on LinkedIn:

“Proud to share our latest publication in the European Heart Journal: “Navigating Cardiotoxicity Risk in Cancer Therapy: The Importance of the HFA-ICOS Score“, co-authored by Doan Ngo and Lloyd Butel Simoes․

As cancer therapies evolve, understanding and mitigating cardiotoxicity has become a cornerstone of cardio-oncology. Our editorial highlights the critical role of cardiovascular risk assessment in cancer patients, emphasizing the ESC HFA-ICOS score as a pivotal tool for stratifying and managing risk.

The editorial accompanies an important paper by Rivero Santana, Teresa López Fernández et al presenting largest cohort of anthracycline-treated patients appropriately stratified by HFA ICOS score

Key takeaways:

– Comprehensive risk assessment is essential for preventing therapy-related cardiac dysfunction.
– The HFA-ICOS score helps tailor surveillance and interventions, ensuring high-risk patients receive the care they need.
– Future directions include integrating AI, advanced biomarkers, and imaging for more personalized care.

Important message on World Cancer Day for all people living with and beyond cancer to look after their heart health during and beyond cancer treatment for better quality of life long-term.

Collaboration and innovation in cardio-oncology are the keys to improving outcomes for patients navigating the dual challenges of cancer and cardiovascular health.”

Navigating cardiotoxicity risk in cancer therapy: the importance of the HFA-ICOS score

Authors: Lloyd Butel Simoes, Doan Ngo and Aaron L. Sverdlov

aaron sverdlov